TRDA Stock Price, Entrada Therapeutics, . Quote, Chart

Market Summary

USD14.98+0.03

Delayed

0.20%

TRDA Alerts

1 major insider buys recently.

Big jump in Earnings (Y/Y)

TRDA Stock Price

View Fullscreen

TRDA RSI Chart

TRDA Valuation

Market Cap

505.7M

Price/Earnings (Trailing)

21.53

Price/Sales (Trailing)

3.1

Price/Free Cashflow

-5.39

TRDA Price/Sales (Trailing)

TRDA Profitability

Return on Equity

8.72%

Return on Assets

4.6%

Free Cashflow Yield

-18.57%

TRDA Fundamentals

TRDA Revenue

Revenue (TTM)

162.9M

Rev. Growth (Qtr)

41.27%

TRDA Earnings

Earnings (TTM)

23.5M

Earnings Growth (Yr)

452.05%

Earnings Growth (Qtr)

346.19%

Breaking Down TRDA Revenue

Last 7 days

4.5%

Last 30 days

22.6%

Last 90 days

4.2%

Trailing 12 Months

18.3%

How does TRDA drawdown profile look like?

TRDA Financial Health

Current Ratio

2.38

TRDA Investor Care

Shares Dilution (1Y)

1.69%

Diluted EPS (TTM)

0.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	162.9M	0	0	0
2023	0	0	0	129.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Entrada Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 09, 2024	kim peter s	bought	31,341	14.2459	2,200	-
May 08, 2024	kim peter s	bought	31,964	14.0442	2,276	-
Apr 08, 2024	kim peter s	bought	35,289	13.573	2,600	-
Mar 28, 2024	kim peter s	bought	20,793	13.7526	1,512	-
Mar 26, 2024	kim peter s	bought	37,509	13.6397	2,750	-
Mar 25, 2024	kim peter s	bought	42,472	13.356	3,180	-
Mar 22, 2024	kim peter s	bought	42,900	13.759	3,118	-
Mar 21, 2024	kim peter s	bought	9,317	13.2353	704	-
Mar 20, 2024	kim peter s	bought	14,280	12.6604	1,128	-
Mar 19, 2024	kim peter s	bought	11,397	12.6633	900	-

Which funds bought or sold TRDA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Plato Investment Management Ltd	unchanged	-	-1,026	15,814	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-11.11	-35,448	178,981	-%
May 15, 2024	Squarepoint Ops LLC	new	-	483,211	483,211	-%
May 15, 2024	DEUTSCHE BANK AG\	added	3.07	-4,758	143,245	-%
May 15, 2024	STATE STREET CORP	added	1.77	-286,509	6,169,480	-%
May 15, 2024	TCG Crossover Management, LLC	unchanged	-	-538,159	8,288,810	0.66%
May 15, 2024	WELLINGTON MANAGEMENT GROUP LLP	reduced	-2.00	-1,260,680	14,550,300	-%
May 15, 2024	MORGAN STANLEY	added	118	780,156	1,524,150	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	reduced	-8.52	-6,400,000	39,016,000	-%
May 15, 2024	72 Investment Holdings, LLC	sold off	-100	-2,604,530	-	-%

Are Funds Buying or Selling TRDA?

Are funds buying TRDA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TRDA

No. of Funds

Unveiling Entrada Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	roche finance ltd	8.2%	2,744,120	SC 13G/A
Feb 14, 2024	redmile group, llc	3.8%	1,283,735	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	9.0%	3,009,673	SC 13G/A
Feb 14, 2023	redmile group, llc	5.9%	1,854,108	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	9.6%	3,014,377	SC 13G/A
Feb 06, 2023	wellington management group llp	3.22%	1,010,351	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	6.4%	2,020,637	SC 13G
Feb 14, 2022	redmile group, llc	6.3%	1,954,420	SC 13G
Feb 14, 2022	roche finance ltd	9.0%	2,813,525	SC 13G
Feb 08, 2022	mrl ventures fund llc	5.6%	1,739,768	SC 13G

Recent SEC filings of Entrada Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 30, 2024	144	Notice of Insider Sale Intent
Apr 29, 2024	144	Notice of Insider Sale Intent
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Entrada Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Entrada Therapeutics, Inc. News

Latest updates

Entrada Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Revenue	41.3%	59.00	42.00	44.00	18.00	25.00
Operating Expenses	2.9%	38.00	37.00	30.00	34.00	31.00
S&GA Expenses	-100.0%	-	9.00	8.00	8.00	8.00
R&D Expenses	1.1%	29.00	28.00	22.00	26.00	23.00
Income Taxes	-90.4%	2.00	19.00	-17.40	14.00	4.00
Net Income	346.2%	23.00	-9.54	35.00	-25.93	-6.67
Net Income Margin	378.3%	0.14*	-0.05*	-	-	-
Free Cashflow	-428.3%	-26.36	-4.99	-25.94	-36.61	202

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	8.9%	511	469	485	494	476	252	274	296	317	306	132	44.00
Current Assets	12.0%	414	370	383	390	434	210	235	254	273	299	124	40.00
Cash Equivalents	7.1%	72.00	68.00	52.00	80.00	228	45.00	57.00	95.00	89.00	291	122	39.00
Net PPE	-1.7%	11.00	11.00	11.00	11.00	9.00	8.00	7.00	8.00	7.00	6.00	6.00	3.00
Liabilities	6.5%	241	227	238	287	246	40.00	41.00	40.00	39.00	7.00	7.00	3.00
Current Liabilities	9.5%	174	159	165	126	148	22.00	22.00	18.00	15.00	7.00	7.00	3.00
Shareholder's Equity	11.1%	269	242	247	207	230	213	233	256	277	299	-	-
Retained Earnings	12.1%	-171	-195	-185	-220	-194	-188	-163	-138	-115	-93.67	-75.22	-42.51
Additional Paid-In Capital	0.9%	441	437	433	429	425	403	400	397	394	392	3.00	1.00
Shares Outstanding	0.5%	34.00	33.00	33.00	33.00	33.00	31.00	31.00	31.00	31.00	31.00	1.00	-
Float	-	-	-	-	431	-	-	-	274	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-535.9%	-25,519	-4,013	-24,492	-35,091	203,399	-27,304	-27,482	-18,009	-20,991	-20,541	-14,075	-7,910	-8,336	-	-
Share Based Compensation	-2.8%	3,733	3,841	3,396	3,119	2,755	2,882	2,707	2,512	1,794	1,458	578	326	164	-	-
Cashflow From Investing	37.3%	26,147	19,043	-3,737	-113,257	-40,444	18,792	-10,134	24,225	-181,533	-1,322	-806	-1,544	-908	-	-
Cashflow From Financing	-70.1%	206	690	368	443	19,536	358	60.00	11.00	50.00	190,755	106	215	116,385	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TRDA Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 59,120	$ 25,260
Operating expenses:
Research and development	28,608	23,102
General and administrative	9,399	7,938
Total operating expenses	38,007	31,040
Income (loss) from operations	21,113	(5,780)
Other income:
Interest and other income	4,214	2,657
Total other income	4,214	2,657
Income (loss) before provision for income taxes	25,327	(3,123)
Provision for income taxes	(1,831)	(3,551)
Net income (loss)	$ 23,496	$ (6,674)
Net income (loss) per share, basic (in dollars per share)	$ 0.70	$ (0.21)
Net income (loss) per share, diluted (in dollars per share)	$ 0.68	$ (0.21)
Weighted-average common shares outstanding, basic (in shares)	33,497,072	32,374,299
Weighted-average common shares outstanding, diluted (in shares)	34,790,925	32,374,299
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities	$ (441)	$ 1,415
Total other comprehensive (loss) income	(441)	1,415
Total comprehensive income (loss)	$ 23,055	$ (5,259)

TRDA Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 68,436	$ 67,602
Marketable securities	258,978	284,367
Collaboration receivable	77,514	5,878
Prepaid expenses and other current assets	9,244	11,924
Total current assets	414,172	369,771
Property and equipment, net	11,002	11,191
Restricted cash	3,950	3,950
Right-of-use assets, operating leases	78,958	81,490
Other non-current assets	2,762	2,790
Total assets	510,844	469,192
Current liabilities:
Accounts payable	2,527	3,277
Accrued expenses and other current liabilities	8,792	11,325
Income taxes payable	5,855	4,024
Operating lease obligations, current portion	8,301	7,909
Deferred revenue, current portion	148,463	132,261
Total current liabilities	173,938	158,796
Operating lease obligations, net of current portion	58,131	60,321
Deferred revenue, net of current portion	9,408	7,715
Total liabilities	241,477	226,832
Commitments and contingencies (Note 11)
Stockholders’ equity:
Common stock, par value $0.0001; 150,000,000 shares authorized; $33,625,117 shares issued and $33,604,053 shares outstanding as of March 31, 2024 and 33,461,771 shares issued and 33,437,296 shares outstanding as of December 31, 2023	3	3
Additional paid‑in capital	441,084	437,132
Accumulated other comprehensive (loss) income	(246)	195
Accumulated deficit	(171,474)	(194,970)
Total stockholders’ equity	269,367	242,360
Total liabilities and stockholders’ equity	$ 510,844	$ 469,192

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

CEO	Mr. Dipal Doshi
WEBSITE	entradatx.com
INDUSTRY	Biotechnology
EMPLOYEES	131

Entrada Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Entrada Therapeutics, Inc.? What does TRDA stand for in stocks?

TRDA is the stock ticker symbol of Entrada Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Entrada Therapeutics, Inc. (TRDA)?

As of Fri May 17 2024, market cap of Entrada Therapeutics, Inc. is 505.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TRDA stock?

You can check TRDA's fair value in chart for subscribers.

What is the fair value of TRDA stock?

You can check TRDA's fair value in chart for subscribers. The fair value of Entrada Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Entrada Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TRDA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Entrada Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TRDA is over valued or under valued. Whether Entrada Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Entrada Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TRDA.

What is Entrada Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TRDA's PE ratio (Price to Earnings) is 21.53 and Price to Sales (PS) ratio is 3.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TRDA PE ratio will change depending on the future growth rate expectations of investors.